Cellbion Co Ltd (308430)

Currency in KRW
24,150.00
0.00(0.00%)
Closed·
308430 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
308430 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
23,550.0025,050.00
52 wk Range
9,930.0029,600.00
Key Statistics
Bid/Ask
24,150.00 / 24,200.00
Prev. Close
24,150
Open
24,600
Day's Range
23,550-25,050
52 wk Range
9,930-29,600
Volume
249.81K
Average Volume (3m)
227.42K
1-Year Change
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
308430 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Cellbion Co Ltd Company Profile

CellBion Co., Ltd. engages in the research and development of radiopharmaceutical products. Its clinical stage pipeline includes 177Lu-PSMA-DGUL, indicated for prostate cancer radiotherapy, currently under Phase 2 clinical stage; 225Ac-Antibody, indicated for multiple cancer types, currently under pre-clinical stage; 225Ac-DGUL, indicated for prostate cancer radiotherapy, currently under pre-clinical stage; 68Ga-Nota-MSA, indicated for cardiovascular disease diagnosis, currently under Phase 2 clinical stage; 99mTc-MSA-ICG, indicated for lymphoscintigraphy SLN mapping, currently under Phase 1 clinical stage; and 68Ga-NGUL, indicated for prostate cancer diagnosis, currently under Phase 2 clinical stage. It is also involved in the development of preclinical stage pipeline comprising 68 Ga-FAP, indicated for solid tumors diagnosis; 225 Ac-FAP, indicated for solid tumors radiotherapy; and peptide-based radioligand therapy and antibody-radionuclide conjugates for undisclosed indications. The company was founded in 2010 and is headquartered in Seoul, South Korea.

Compare 308430 to Peers and Sector

Metrics to compare
308430
Peers
Sector
Relationship
P/E Ratio
−42.4x−2.0x−0.5x
PEG Ratio
-0.030.00
Price/Book
11.0x1.2x2.6x
Price / LTM Sales
120.5x1.8x3.3x
Upside (Analyst Target)
-48.2%42.8%
Fair Value Upside
Unlock10.3%6.5%Unlock

Earnings

Latest Release
May 13, 2025
EPS / Forecast
-111.49 / --
Revenue / Forecast
479.58M / --
EPS Revisions
Last 90 days

308430 Income Statement

People Also Watch

45,000
000990
-2.07%
26,550
028050
+3.11%
66,300
034020
+2.31%
19,840
030000
-0.20%
19,600
010140
-0.76%

FAQ

What Stock Exchange Does Cellbion Trade On?

Cellbion is listed and trades on the KOSDAQ stock exchange.

What Is the Stock Symbol for Cellbion?

The stock symbol for Cellbion is "308430."

What Is the Cellbion Market Cap?

As of today, Cellbion market cap is 309.51B.

What Is Cellbion's Earnings Per Share (TTM)?

The Cellbion EPS (TTM) is -570.21.

From a Technical Analysis Perspective, Is 308430 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Cellbion Stock Split?

Cellbion has split 0 times.

How Many Employees Does Cellbion Have?

Cellbion has 0 employees.

What is the current trading status of Cellbion (308430)?

As of 06 Aug 2025, Cellbion (308430) is trading at a price of 24,150.00, with a previous close of 24,150.00. The stock has fluctuated within a day range of 23,550.00 to 25,050.00, while its 52-week range spans from 9,930.00 to 29,600.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.